O slideshow foi denunciado.

ARDS Market | Acute respiratory distress syndrome Market

2

Compartilhar

1 de 9
1 de 9

ARDS Market | Acute respiratory distress syndrome Market

2

Compartilhar

Baixar para ler offline

Acute Respiratory Distress Syndrome (ARDS) is a life-threatening severe orphan disease in which the air sacs present in alveoli are filled with fluid and lower the amount of oxygen in the blood. Thus, enough oxygen is not supplied to the body. Inflammation may occur throughout the lungs.

Acute Respiratory Distress Syndrome (ARDS) is a life-threatening severe orphan disease in which the air sacs present in alveoli are filled with fluid and lower the amount of oxygen in the blood. Thus, enough oxygen is not supplied to the body. Inflammation may occur throughout the lungs.

Mais Conteúdo rRelacionado

ARDS Market | Acute respiratory distress syndrome Market

  1. 1. MARKET INSIGHTS, EPIDEMIOLOGY & MARKET FORECAST-2027 ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS)
  2. 2.  Acute Respiratory Distress Syndrome (ARDS) is a life- threatening severe orphan disease in which the air sacs present in alveoli are filled with fluid and lower the amount of oxygen in blood. Thus, enough oxygen is not supplied to the body. Inflammation may occur throughout the lungs.  ARDS is also classified on the basis of severity of disease as Mild ARDS, Moderate ARDS and Severe ARDS by Berlin definition. It is generally characterized into three stages such as exudative stage, fibro proliferative (or proliferative) stage, resolution and recovery stage. 2 DelveInsight © 2018 | All rights reserved ACUTE RESPIRATORY DISTRESS SYNDROME
  3. 3. 3 DelveInsight © 2018 | All rights reserved EPIDEMIOLOGY INSIGHTS DelveInsight estimates ARDS incidence has varied from 1.3 to 22 per 100,000 person years. Cross-sectional studies demonstrate that patients with ARDS represent approximately 5% of hospitalized, mechanically ventilated patients. Mild ARDS represents only 25% of patients with ARDS, approximately 75% of patients are reported with moderate or severe ARDS. ARDS occurrence varies consistently, ranging from 10.6 per 100,000 person-years in Finland, to 17.9 per 100,000 person-years in Scandinavia, to 25.5 per 100,000 person-years in Spain. 1 2 3 4
  4. 4. Extensive research and development activities of pharmaceutical companies are being carried out for developing the therapies for ARDS along with the emerging therapies in the pipeline Market Size of ARDS in the 7MM was found to be XXX in 2016 MARKET INSIGHTS Owing to the launch of upcoming therapies, the market size shall increase significantly during forecast period (2018-2027) There are many potential pipeline drugs expected to enter ARDS market by XXXX and subsequent years. Expected launch of BioMark Pharmaceuticals’ BIO-11006, Techpool, Bio-Pharma‘s Ulinastatin and other therapies shall impact the market size of ARDS ARDS 4 DelveInsight © 2018 | All rights reserved
  5. 5. 5 DelveInsight © 2018 | All rights reserved 03 02 01 K E Y P L A Y E R S Faron Pharmaceuticals Techpool Bio-Pharma BioMarck Pharmaceuticals
  6. 6. 6 DelveInsight © 2018 | All rights reserved COMPLETE INFORMATION For complete information please click below Or Write to us at info@delveinsight.com CLICK HERE
  7. 7. 01 02 03 ABOUT DELVEINSIGHT 7 DelveInsight, market research and consulting firm, provides end to end comprehensive solutions to the Life Science Industry. We help our customers in best decision making through our expertise in research & analysis and comes out with unmatched data & forecasts Vision “Insight across the value chain” to help organizations make important business decisions through the use and analysis of actionable market intelligence Mission  To be the most trusted marketing research firm & business consulting firm worldwide.  To be a renowned and premier data driven solution providers among Pharma & Biotech companies. DelveInsight © 2018 | All rights reserved
  8. 8. 8 DelveInsight © 2018 | All rights reserved SERVICE OFFERINGS AT DELVEINSIGHT Comprehensive solution for strategic business decisions • Trends Analysis • Physicians & Patients Perception • KOLs • Market Size • Market Dynamics • Market Assessment Access over 3000+ Reports • API • Market & Pipeline • Indication & Epidemiology • Drug Sales Forecast • Indication Forecast • Late Stage Pipeline Analysis • Asset Prioritization • Brand Optimization • Portfolio Expansion Opportunity Assessment for • Licensing • Market Access • Partnership • Competitive landscape • Clinical Trials • Therapeutic Assessment • Primary Analytics • News-Letters • Conference Tracking • Clinical Trials Tracking Market Intelligence Consulting SociAlytics Pipeline Forecasting
  9. 9. Add a Slide Title - 5 Contact Us: info@delveinsight.com +91-11-4568 9769 www.delveinsight.com blog/delveInsight/ twitter/delveInsight LinkedIn/delveInsight

×